In the BRAF-wild-type group, 7 out of 10 cases were KRAS mutants, and 4 of them were located on the right side, indicating that KRAS mutants dominated in the right colon, which is one of the reasons why advanced left CRC can benefit from cetuximab and have a better prognosis than advanced right CRC [19]. This evidence concerns the gene BRAF and colorectal carcinoma.